MHH · Mastech Digital, Inc. · Insider Trading

The reporting person is the trustee and a contingent residual beneficiary of the Rachel Lynn Shaw Trust.

RSUs granted by the Issuer pursuant to its Stock Incentive Plan, as amended and restated effective as of May 14, 2024 and further amended on May 14, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

On August 10, 2026, Mr. Sugantharaman received an award of 20,000 restricted stock units of the Issuer ("RSUs"). The RSUs will vest as follows: (i) 6,667 RSUs will vest on August 10, 2027; (ii) 6,667 RSUs will vest on August 10, 2028; and (iii) 6,666 RSUs will vest on August 10, 2029.

This purchase was executed through multiple trades at prices ranging from $6.95 to $7.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee and a contingent residual beneficiary of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $6.78 to $7.13. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee and a contingent residual beneficiary of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $6.16 to $6.21. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $6.04 to $6.10. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $5.89 to $6.00. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $6.92 to $6.99. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

This Amendment to Form 4 is being filed to correct the number of shares of Common Stock shown as beneficially owned by the Rachel Lynn Shaw Trust following the purchases made on January 29, 2026 and January 30, 2026, and to include the number of shares of Common Stock owned directly by the reporting person. In addition, the prior Form 4 filings filed by the reporting person on December 11, 2025, September 22, 2025, September 2, 2025, August 22, 2025 and July 17, 2025 also misstated the number of shares of Common Stock beneficially owned by the Rachel Lynn Shaw Trust and did not separately state the number of shares of Common Stock directly owned by the reporting person.

(Continued from footnote 2) With respect to the Form 4 filed on December 11, 2025, the Rachel Lynn Shaw Trust owned the following: 28,763 shares of Common Stock following the purchase of 2,758 shares of Common Stock on December 9, 2025, and 30,078 shares of Common Stock following the purchase of 1,315 shares of Common Stock on December 10, 2025. With respect to the Form 4 filed on September 22, 2025, the Rachel Lynn Shaw Trust owned 26,005 shares of Common Stock following the purchase of 4,537 shares of Common Stock on September 19, 2025. With respect to the Form 4 filed on September 2, 2025, the Rachel Lynn Shaw Trust owned 21,468 shares of Common Stock following the purchase of 3,500 shares of Common Stock on August 29, 2025. With respect to the Form 4 filed on August 22, 2025, the Rachel Lynn Shaw Trust owned 17,968 shares of Common Stock following the purchase of 4,800 shares of Common Stock on August 21, 2025.

(Continued from footnote 3) With respect to the Form 4 filed on July 17, 2025, the Rachel Lynn Shaw Trust owned the following: 12,368 shares of Common Stock following the purchase of 3,068 shares of Common Stock on July 15, 2025, 12,668 shares of Common Stock following the purchase of 300 shares of Common Stock on July 16, 2025, and 13,168 shares of Common Stock following the purchase of 500 shares of Common Stock on July 16, 2025. The Form 4 filed on July 17, 2025 also incorrectly stated that the reporting person is a contingent residual beneficiary of the Rachel Lynn Shaw Trust. At all times from July 15, 2025 through March 3, 2026, the reporting person has directly owned 1,310,100 shares of Common Stock.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $7.37 to $7.57. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

This purchase was executed through multiple trades at prices ranging from $6.90 to $7.39. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $7.62 to $7.90. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $7.96 to $8.0999. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $7.73 to $7.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee of the Rachel Lynn Shaw Trust.

This purchase was executed through multiple trades at prices ranging from $7.42 to $8.03. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

The reporting person is the trustee and a contingent residual beneficiary of the Rachel Lynn Shaw Trust.

On April 14, 2025, Mr. Sugantharaman received an award of a non-qualified stock options to purchase 150,000 shares of common stock of the Company. The options will vest as follows: (i) 18,750 shares will vest on April 14, 2026; (ii) 18,750 shares will vest on April 14, 2027; (iii) 18,750 shares will vest on April 14, 2028; (iv) 18,750 shares will vest on April 14, 2029; (v) 37,500 shares will vest on the first date during Mr. Sugantharaman's term of employment that the Company's Quarterly Average Market Capitalization (as defined in the stock option agreement executed by Mr. Sugantharaman with respect to the options) is greater than $300,000,000; (vi) 18,750 shares will vest on the first date during Mr. Sugantharaman's term of employment that the Company's Quarterly Average Market Capitalization is greater than $450,000,000; and

(Continued from footnote 1) (vii) 18,750 shares will vest on the first date during Mr. Sugantharaman's term of employment that the Company's Quarterly Average Market Capitalization is greater than $600,000,000.

Represents 5,535 shares of restricted stock granted on January 30, 2025. The restricted shares shall vest on January 30, 2026.

Represents 5,535 shares of restricted stock granted on January 30, 2025. The restricted shares shall vest on January 30, 2026.

Represents 5,535 shares of restricted stock granted on January 30, 2025. The restricted shares shall vest on January 30, 2026.

Represents 5,535 shares of restricted stock granted on January 30, 2025. The restricted shares shall vest on January 30, 2026.

On January 6, 2025, Mr. Patel received an award of a non-qualified stock option to purchase 702,358 shares of common stock of the Company. The option will vest as follows: (i) 87,795 shares will vest on January 6, 2026; (ii) 87,795 shares will vest on January 6, 2027; (iii) 87,795 shares will vest on January 6, 2028; (iv) 87,794 shares will vest on January 6, 2029; (v) 175,589 shares will vest on the first date during Mr. Patel's term of employment that the Company's Quarterly Average Market Capitalization (as defined in the stock option agreement executed by Mr. Patel with respect to the options) is greater than $300,000,000;

(Continued From Footnote 1) (vi) 87,795 shares will vest on the first date during Mr. Patel's term of employment that the Company's Quarterly Average Market Capitalization is greater than $450,000,000; and (vii) 87,795 shares will vest on the first date during Mr. Patel's term of employment that the Company's Quarterly Average Market Capitalization is greater than $600,000,000.

Represents 3,506 shares of restricted stock granted on August 12, 2024. The restricted shares shall vest on January 30, 2025.

Represents 3,506 shares of restricted stock granted on August 12, 2024. The restricted shares shall vest on January 30, 2025.

Represents 3,506 shares of restricted stock granted on August 12, 2024. The restricted shares shall vest on January 30, 2025.

Represents 7,403 shares of restricted stock granted on January 30, 2024. The restricted shares shall vest on January 30, 2025.

Represents 7,403 shares of restricted stock granted on January 30, 2024. The restricted shares shall vest on January 30, 2025.

Represents 7,403 shares of restricted stock granted on January 30, 2024. The restricted shares shall vest on January 30, 2025.

Represents 7,403 shares of restricted stock granted on January 30, 2024. The restricted shares shall vest on January 30, 2025.

Represents 4,981 shares of restricted stock granted on January 30, 2023. The restricted shares shall vest on January 30, 2024.

Represents 4,981 shares of restricted stock granted on January 30, 2023. The restricted shares shall vest on January 30, 2024.

Represents 4,981 shares of restricted stock granted on January 30, 2023. The restricted shares shall vest on January 30, 2024.

Represents 4,981 shares of restricted stock granted on January 30, 2023. The restricted shares shall vest on January 30, 2024.

The original Form 4, filed on December 20, 2021, is being amended by this Form 4 amendment to update the report with the price of the securities sold as determined by a third-party written appraisal.

On November 14, 2022, Mr. Fleishman received an award of a non-qualified stock option to purchase 300,000 shares of common stock of the Company. The option will vest in one-third increments beginning on each of November 14, 2023, November 14, 2024, and November 14, 2025.

On November 14, 2022, Mr. Cronin received an award of non-qualified stock option to purchase 100,000 shares of common stock of the Company. The option will vest in one-third increments on each of November 14, 2024, November 14, 2025, and November 14, 2026.

On November 14, 2022, Mr. Gupta received an award of non-qualified stock option to purchase 150,000 shares of common stock of the Company. The option will vest in one-third increments on each of November 14, 2024, November 14, 2025, and November 14, 2026.

Represents 2,675 shares of restricted stock granted on April 1, 2022. The restricted shares shall vest on January 30, 2023.

On March 28, 2022, Mr. Venkateshwaran received an award of a non-qualified stock option to purchase 400,000 shares of common stock of the Company. The option will vest in four equal annual installments beginning on March 28, 2023.

Represents 3,768 shares of restricted stock granted on January 30, 2022. The restricted shares shall vest on January 30, 2023.

Represents 3,768 shares of restricted stock granted on January 30, 2022. The restricted shares shall vest on January 30, 2023.

Represents 3,768 shares of restricted stock granted on January 30, 2022. The restricted shares shall vest on January 30, 2023.

40,000 shares shall vest on February 10, 2022. 40,000 additional shares shall vest on February 10, 2023 and thereafter in equal 40,000 share installments through February 10, 2025.

3,985 Restricted Shares shall vest on January 30, 2022.

3,985 Restricted Shares shall vest on January 30, 2022.

3,985 Restricted Shares shall vest on January 30, 2022.